Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

Oncogene

Volumn 33, Issue 39, 2014, Pages 4724-4734

  Chen, X ^a,b   Wu, Q ^b   Tan, L ^c   Porter, D ^c   Jager, M J ^d   Emery, C ^c   Bastian, B C ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combined PKC and MEK inhibition; GNAQ GNA11; MAPK signaling; Melanoma; PKC inhibitor; Protein kinase C

Indexed keywords

AHT 956; BINIMETINIB; GNA11 PROTEIN; GNAQ PROTEIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; ONCOPROTEIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SOTRASTAURIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; GNA11 PROTEIN, HUMAN; GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MELANOCYTE; MELANOMA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; TUMOR GROWTH; TUMOR REGRESSION; UVEA MELANOMA; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HUMAN; IC50; MELANOMA; METABOLISM; MISSENSE MUTATION; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME; UVEAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE KINASES; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; MUTATION, MISSENSE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; SIGNAL TRANSDUCTION; TUMOR BURDEN; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908316203     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.418     Document Type: Article

References (50)

1. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005;18:75-84.
2. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-251.
3. McLean IW, Saraiva VS, Burnier Jr MN. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004;39:343-350.
4. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-389 (discussion 390).
5. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
6. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-2199.
7. Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 2009;4:e6833.
8. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
9. Hubbard KB, Hepler JR. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal 2006;18:135-150.
10. Markby DW, Onrust R, Bourne HR. Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 1993;262:1895-1901.
11. Kalinec G, Nazarali AJ, Hermouet S, Xu N, Gutkind JS. Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells. Mol Cell Biol 1992;12:4687-4693.
12. Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene 2007;26:3122-3142.
13. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007;7:554-562.
14. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-294.
15. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982;257:7847-7851.
16. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 1983;258:11442-11445.
17. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res 2006;12:5336-5345.
18. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011;11:185-199.
19. Urtreger AJ, Kazanietz MG, Bal De Kier Joffe ED. Contribution of individual PKC isoforms to breast cancer progression. IUBMB Life 2012;64:18-26.
20. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 2012;11:1905-1914.
21. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 2012;7:e29622.
22. Herget T, Oehrlein SA, Pappin DJ, Rozengurt E, Parker PJ. The myristoylated alanine-rich C-kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C. Eur J Biochem 1995;233:448-457.
23. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993;268:1501-1504.
24. Heemskerk FM, Chen HC, Huang FL. Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain. Biochem Biophys Res Commun 1993;190:236-241.
25. Thelen M, Rosen A, Nairn AC, Aderem A. Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. Nature 1991;351:320-322.
26. Wagner J, Von Matt P, Sedrani R, Albert R, Cooke N, Ehrhardt C et al. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl) quinazolin-4-yl]pyrrole-2, 5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009;52:6193-6196.
27. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-2653.
28. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-972.
29. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
30. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-4861.
31. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
32. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659-666.
33. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009;106:4519-4524.
34. Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 2006;95:829-834.
35. Gronberg BH, Ciuleanu T, Flotten O, Knuuttila A, Abel E, Langer SW et al. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer 2012;78:63-69.
36. Clement-Duchene C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE et al. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 2012;78:57-62.
37. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987;39:414-418.
38. Arita Y, O'Driscoll KR, Weinstein IB. Growth of human melanocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation. Cancer Res 1992;52:4514-4521.
39. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993;364:249-252.
40. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogenactivated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-798.
41. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 1996;271:23512-23519.
42. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362.
43. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, Gilbert D et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal 2010;3: ra90.
44. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102:1724-1730.
45. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;703:1694-1730.
46. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364:772-774.
47. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-567.
48. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008;68:6145-6153.
49. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res 2012;25:182-187.
50. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-446.